Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study

Ocrelizumab: a new milestone in multiple sclerosis therapy

Patricia Mulero
Luciana Midaglia
Xavier Montalban

May 2018

B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in the...

Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis

Hauser S. L.
Bar-Or A.
Comi G.
Giovannoni G.
Hartung H. -P.
Hemmer B.
Lublin F.
Montalban X.
Rammohan K. W.
Selmaj K.
Traboulsee A.
Wolinsky J. S.
Arnold D. L.
Klingelschmitt G.
Masterman D.
Fontoura P.
Belachew S.
Chin P.
Mairon N.
Garren H.
Kappos L
. Uccelli A.

January 2017

BACKGROUNDB cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoc...

Ocrelizumab versus placebo in primary progressive multiple sclerosis

X. Montalban
S. L. Hauser
L. Kappos
D. L. Arnold
A. Bar‑Or
G. Comi
J. de Seze
G. Giovannoni
H. -P. Hartung
B. Hemmer
F. Lublin
K. W. Rammohan
K. Selmaj
A. Traboulsee
A. Sauter
D. Masterman
P. Fontoura
S. Belachew
H. Garren
N. Mairon
P. Chin
J. S. Wolinsky
Uccelli A
for the ORATORIO Clinical Investigators

January 2017

BACKGROUNDAn evolving understanding of the immunopathogenesis of multiple sclerosis suggests that de...

Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study

Capasso, Nicola
Palladino, Raffaele
Cerbone, Vincenza
Spiezia, Antonio Luca
Covelli, Bianca
Fiore, Antonia
Lanzillo, Roberta
Carotenuto, Antonio
Petracca, Maria
Stanziola, Lucia
Scalia, Giulia
Brescia Morra, Vincenzo
Moccia, Marcello

January 2022

We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal antibody for the tr...

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients

Stefan Gingele
Thais Langer Jacobus
Franz Felix Konen
Martin W. Hümmert
Kurt-Wolfram Sühs
Philipp Schwenkenbecher
Jonas Ahlbrecht
Nora Möhn
Lars H. Müschen
Lena Bönig
Sascha Alvermann
Reinhold E. Schmidt
Martin Stangel
Roland Jacobs
Thomas Skripuletz

December 2018

Ocrelizumab, a humanized monoclonal anti-CD20 antibody, has shown pronounced effects in reduction of...

Confirmation of CD19+ B-Lymphocyte Depletion Prior to Intake of the Second Dose of Ocrelizumab in Multiple Sclerosis Patients

Marija Radmilo
Sanda Pavelin
Igor Vujović
Joško Šoda
Maja Rogić Vidaković

January 2023

The aim of the retrospective study was to compare the immunophenotyping of T-lymphocytes, B-lymphocy...

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects

Per Soelberg Sorensen
Morten Blinkenberg

January 2016

B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in the ac...

Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis

Capasso N.
Nozzolillo A.
Scalia G.
Lanzillo R.
Carotenuto A.
De Angelis M.
Petruzzo M.
Saccà Francesco
Russo C. V.
Brescia Morra V.
Moccia M.

January 2021

Background: We aim to directly compare changes in lymphocyte subpopulations between chimeric (rituxi...

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers

Margoni, Monica
Preziosa, Paolo
Tortorella, Paola
Filippi, Massimo
Rocca, Maria A

January 2022

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disease affe...

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.

Mathias, A.
Pantazou, V.
Perriot, S.
Canales, M.
Jones, S.
Oberholster, L.
Moulin, M.
Fenwick, C.
Bernard-Valnet, R.
Théaudin, M.
Pot, C.
Du Pasquier, R.A.

March 2023

Depleting CD20 <sup>+</sup> B cells is the primary mechanism by which ocrelizumab (OCRE)...

Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells

Abbadessa G.
Maida E.
Miele G.
Lavorgna L.
Marfia G. A.
Valentino P.
De Martino A.
Cavalla P.
Bonavita S.

January 2022

Background: In the phase III, OPERA I and OPERA II, clinical trial lymphopenia was reported in 20.7%...

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic

de Sèze, Jérôme
Maillart, Elisabeth
Gueguen, Antoine
Laplaud, David A. A.
Michel, Laure
Thouvenot, Eric
Zephir, Helene
Zimmer, Luc
Biotti, Damien
Liblau, Roland

January 2023

International audienceThe immune system plays a significant role in multiple sclerosis. While MS was...

Monoclonal antibodies in the treatment of multiple sclerosis: from clinical research to practical application

N. Yu. Lashch

July 2020

Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating and neurodegenerative dis...

Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis

Garcia, Alexandra
Dugast, Emilie
Shah, Sita
Morille, Jérémy
Lebrun-Frenay, Christine
Thouvenot, Eric
de Sèze, Jérôme
Le Page, Emmanuelle
Vukusic, Sandra
Maurousset, Aude
Berger, Eric
Casez, Olivier
Labauge, Pierre
Ruet, Aurélie
Raposo, Catarina
Bakdache, Fabien
Buffels, Régine
Le Frère, Fabienne
Nicot, Arnaud
Wiertlewski, Sandrine
Gourraud, Pierre-Antoine
Berthelot, Laureline
Laplaud, David

February 2023

Background and objectives: Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly e...

Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis

O. V. Boyko
S. V. Petrov
N. Yu. Lashch
M. R. Guseva
A. N. Boyko

March 2019

One of the promising areas in the pathogenetic treatment of multiple sclerosis (MS) is anti-B-cell t...

Ocrelizumab: a new milestone in multiple sclerosis therapy

Patricia Mulero
Luciana Midaglia
Xavier Montalban

May 2018

B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in the...

Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis

Hauser S. L.
Bar-Or A.
Comi G.
Giovannoni G.
Hartung H. -P.
Hemmer B.
Lublin F.
Montalban X.
Rammohan K. W.
Selmaj K.
Traboulsee A.
Wolinsky J. S.
Arnold D. L.
Klingelschmitt G.
Masterman D.
Fontoura P.
Belachew S.
Chin P.
Mairon N.
Garren H.
Kappos L
. Uccelli A.

January 2017

BACKGROUNDB cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoc...

Ocrelizumab versus placebo in primary progressive multiple sclerosis

X. Montalban
S. L. Hauser
L. Kappos
D. L. Arnold
A. Bar‑Or
G. Comi
J. de Seze
G. Giovannoni
H. -P. Hartung
B. Hemmer
F. Lublin
K. W. Rammohan
K. Selmaj
A. Traboulsee
A. Sauter
D. Masterman
P. Fontoura
S. Belachew
H. Garren
N. Mairon
P. Chin
J. S. Wolinsky
Uccelli A
for the ORATORIO Clinical Investigators

January 2017

BACKGROUNDAn evolving understanding of the immunopathogenesis of multiple sclerosis suggests that de...

Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study

Capasso, Nicola
Palladino, Raffaele
Cerbone, Vincenza
Spiezia, Antonio Luca
Covelli, Bianca
Fiore, Antonia
Lanzillo, Roberta
Carotenuto, Antonio
Petracca, Maria
Stanziola, Lucia
Scalia, Giulia
Brescia Morra, Vincenzo
Moccia, Marcello

January 2022

We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal antibody for the tr...

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients

Stefan Gingele
Thais Langer Jacobus
Franz Felix Konen
Martin W. Hümmert
Kurt-Wolfram Sühs
Philipp Schwenkenbecher
Jonas Ahlbrecht
Nora Möhn
Lars H. Müschen
Lena Bönig
Sascha Alvermann
Reinhold E. Schmidt
Martin Stangel
Roland Jacobs
Thomas Skripuletz

December 2018

Ocrelizumab, a humanized monoclonal anti-CD20 antibody, has shown pronounced effects in reduction of...

Confirmation of CD19+ B-Lymphocyte Depletion Prior to Intake of the Second Dose of Ocrelizumab in Multiple Sclerosis Patients

Marija Radmilo
Sanda Pavelin
Igor Vujović
Joško Šoda
Maja Rogić Vidaković

January 2023

The aim of the retrospective study was to compare the immunophenotyping of T-lymphocytes, B-lymphocy...

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects

Per Soelberg Sorensen
Morten Blinkenberg

January 2016

B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in the ac...

Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis

Capasso N.
Nozzolillo A.
Scalia G.
Lanzillo R.
Carotenuto A.
De Angelis M.
Petruzzo M.
Saccà Francesco
Russo C. V.
Brescia Morra V.
Moccia M.

January 2021

Background: We aim to directly compare changes in lymphocyte subpopulations between chimeric (rituxi...

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers

Margoni, Monica
Preziosa, Paolo
Tortorella, Paola
Filippi, Massimo
Rocca, Maria A

January 2022

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disease affe...

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.

Mathias, A.
Pantazou, V.
Perriot, S.
Canales, M.
Jones, S.
Oberholster, L.
Moulin, M.
Fenwick, C.
Bernard-Valnet, R.
Théaudin, M.
Pot, C.
Du Pasquier, R.A.

March 2023

Depleting CD20 <sup>+</sup> B cells is the primary mechanism by which ocrelizumab (OCRE)...

Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells

Abbadessa G.
Maida E.
Miele G.
Lavorgna L.
Marfia G. A.
Valentino P.
De Martino A.
Cavalla P.
Bonavita S.

January 2022

Background: In the phase III, OPERA I and OPERA II, clinical trial lymphopenia was reported in 20.7%...

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic

de Sèze, Jérôme
Maillart, Elisabeth
Gueguen, Antoine
Laplaud, David A. A.
Michel, Laure
Thouvenot, Eric
Zephir, Helene
Zimmer, Luc
Biotti, Damien
Liblau, Roland

January 2023

International audienceThe immune system plays a significant role in multiple sclerosis. While MS was...

Monoclonal antibodies in the treatment of multiple sclerosis: from clinical research to practical application

N. Yu. Lashch

July 2020

Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating and neurodegenerative dis...

Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis

Garcia, Alexandra
Dugast, Emilie
Shah, Sita
Morille, Jérémy
Lebrun-Frenay, Christine
Thouvenot, Eric
de Sèze, Jérôme
Le Page, Emmanuelle
Vukusic, Sandra
Maurousset, Aude
Berger, Eric
Casez, Olivier
Labauge, Pierre
Ruet, Aurélie
Raposo, Catarina
Bakdache, Fabien
Buffels, Régine
Le Frère, Fabienne
Nicot, Arnaud
Wiertlewski, Sandrine
Gourraud, Pierre-Antoine
Berthelot, Laureline
Laplaud, David

February 2023

Background and objectives: Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly e...

Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis

O. V. Boyko
S. V. Petrov
N. Yu. Lashch
M. R. Guseva
A. N. Boyko

March 2019

One of the promising areas in the pathogenetic treatment of multiple sclerosis (MS) is anti-B-cell t...

Ocrelizumab: a new milestone in multiple sclerosis therapy

Patricia Mulero
Luciana Midaglia
Xavier Montalban

May 2018

B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in the...

Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis

Hauser S. L.
Bar-Or A.
Comi G.
Giovannoni G.
Hartung H. -P.
Hemmer B.
Lublin F.
Montalban X.
Rammohan K. W.
Selmaj K.
Traboulsee A.
Wolinsky J. S.
Arnold D. L.
Klingelschmitt G.
Masterman D.
Fontoura P.
Belachew S.
Chin P.
Mairon N.
Garren H.
Kappos L
. Uccelli A.

January 2017

BACKGROUNDB cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoc...

Ocrelizumab versus placebo in primary progressive multiple sclerosis

X. Montalban
S. L. Hauser
L. Kappos
D. L. Arnold
A. Bar‑Or
G. Comi
J. de Seze
G. Giovannoni
H. -P. Hartung
B. Hemmer
F. Lublin
K. W. Rammohan
K. Selmaj
A. Traboulsee
A. Sauter
D. Masterman
P. Fontoura
S. Belachew
H. Garren
N. Mairon
P. Chin
J. S. Wolinsky
Uccelli A
for the ORATORIO Clinical Investigators

January 2017

BACKGROUNDAn evolving understanding of the immunopathogenesis of multiple sclerosis suggests that de...

Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study

Abstract

Extracted data

Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study

Abstract

Extracted data

Related items

Related items